These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8721956)

  • 1. Expression of c-erbB2 oncogene product in different tumours and its standardised evaluation.
    Tannapfel A; Kühn R; Kessler H; Wittekind C
    Anal Cell Pathol; 1996 Mar; 10(2):149-60. PubMed ID: 8721956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytochemical localization of c-erbB-2 protein in transitional cell carcinoma of the urinary bladder.
    Coombs LM; Oliver S; Sweeney E; Knowles M
    J Pathol; 1993 Jan; 169(1):35-42. PubMed ID: 8094432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
    Looi LM; Cheah PL; Yap SF
    Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors].
    Zhang Z; Xu G; Liu S
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):287-9. PubMed ID: 11038761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of c-erbB2 oncoprotein expression in stomach carcinoma].
    Gong Z; Luo E; Lu Q
    Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):299-301. PubMed ID: 9387327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer.
    Rajkumar T; Stamp GW; Pandha HS; Waxman J; Gullick WJ
    J Pathol; 1996 Aug; 179(4):381-5. PubMed ID: 8869284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection by immunohistochemistry of c-erbB2 oncoprotein in breast carcinomas and benign mammary lesions.
    Edorh A; Leroux A; N'sossani B; Parache RM; Rihn B
    Cell Mol Biol (Noisy-le-grand); 1999 Sep; 45(6):831-40. PubMed ID: 10541479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases.
    Gårdmark T; Wester K; De la Torre M; Carlsson J; Malmström PU
    BJU Int; 2005 May; 95(7):982-6. PubMed ID: 15839918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC4 and ErbB2 expression in squamous cell carcinoma of the upper aerodigestive tract: correlation with clinical outcomes.
    Weed DT; Gomez-Fernandez C; Yasin M; Hamilton-Nelson K; Rodriguez M; Zhang J; Carraway KL
    Laryngoscope; 2004 Aug; 114(8 Pt 2 Suppl 101):1-32. PubMed ID: 15284539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder?
    Amsellem-Ouazana D; Bièche I; Molinié V; Elie C; Vieillefond A; Tozlu S; Botto H; Debré B; Lidereau R
    Eur Urol; 2006 Jun; 49(6):1035-42; discussion 1042-3. PubMed ID: 16466848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
    Looi LM; Cheah PL
    Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
    el-A Helal T; Khalifa A; Kamel AS
    Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression level of c-erbB-2 protein correlates with the prognosis of patients with colorectal cancer].
    Zhou Z; Wan D; Zhang C
    Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):139-41. PubMed ID: 11783020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
    Sharma BK; Ray A; Kaur S; Gupta S
    Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-erbB2 oncoprotein: prognostic marker in breast cancer.
    Roşian A; Lazăr E; Dema A
    Rom J Morphol Embryol; 2005; 46(2):99-104. PubMed ID: 16286993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The molecular biology of bladder carcinoma].
    Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.